Posted on

Interstitial cystitis treatment for pain cbd oil

The CBD-IC Randomized Controlled Trial: Evaluation of Hemp Cannabidiol SuppositoRies for Pain and Urinary SymptOms in INterstitial Cystitis (CHRONIC) (CHRONIC)

This study seeks to exploit bladder cannabidiol receptors as a therapeutic drug target by conducting a double-masked, placebo-controlled randomized trial evaluating the effects of vaginal hemp cannabidiol (CBD) suppositories on lower urinary tract symptoms (LUTS), pain severity, and sexual function.

Condition or disease Intervention/treatment Phase
Interstitial Cystitis Bladder Pain Syndrome Drug: Cannabidiol vaginal suppository Drug: Placebo vaginal suppository Phase 1

Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS) is a chronic inflammatory disease with an insidious course and is detrimental weight to women’s quality of life, sexual function, and general health. IC/BPS affects nearly 1.2 million women in the United States and although there are currently six lines of treatment, they lack high level evidence and sufficient efficacy. New therapies are in high demand. As the cannabis industry gains popularity in medicine, research has revealed prevalent expression of cannabinoid receptors in bladder detrusor muscle and urothelium suggesting a novel drug target for IC/BPS. This study seeks to exploit this target by conducting a double-masked, placebo-controlled randomized trial evaluating the effects of vaginal hemp cannabidiol (CBD) suppositories on lower urinary tract symptoms (LUTS), pain severity, and sexual function. Women with diagnosed IC/BPS will be randomized to treatment with a placebo vaginal suppository or a hemp CBD vaginal suppository. We will monitor changes in their LUTS, pain, and sexual function using validated questionnaires. Our goal is to evaluate whether CBD is an effective, low-risk and less invasive treatment option for IC/BPS. Attainment of this goal would demonstrate a potential novel use for CBD in our Urogynecology patient population.

CBD for Interstitial Cystitis – Does it Help?

Interstitial Cystitis (IC) is a condition that causes long-term pelvic pain. If you have ever had a urinary tract infection (UTI), you understand the distress this bladder condition causes. It tends to affect people in their 30s and 40s and is much more common in women than men.

Still, unlike UTI, which antibiotics can cure, Interstitial Cystitis does not have a cure, and it can have a significant impact on your daily life, physical and emotional health, and relationships. Fortunately, various treatments can help relieve the symptoms.

Things that can help relieve the pain of these symptoms include lifestyle changes. The traditional therapies include dietary modifications, avoiding certain foods or drinks, reducing stress, pelvic floor therapy, and cannabis.

Cannabis is one of the most practical ways to deal with a chronic condition like IC, and it has been used medicinally for centuries. Cannabis-based products, such as CBD oils and CBD lubricants, have positive effects, can help to decrease inflammation, and potentially alleviate pelvic pain.

Does CBD Lube Work For Interstitial Cystitis?

In our body, we can find multiple cannabinoid receptors that endocannabinoids can bind to, including the lower urinary tract; this means that CBD lubricants are helpful treatments for bladder conditions such as Interstitial Cystitis.

In fact, CBD has effects on people diagnosed with many different illnesses and is proven to do more than relieve pain. Still, it also helps improve sleep quality, which potentially reduces the pain throughout the day and in the mornings also helps with inflammations. CBD’s therapeutic effects are numerous, which is why it would work for all the pains and symptoms that Interstitial Cystitis causes.

Unfortunately, the use of CBD for Interstitial Cystitis is only supported by anecdotal evidence. Some hopeful findings say that cannabinoid receptors are present in the lower urinary tract, which means the bladder walls line up with cannabinoid receptors. So, if systemic cannabinoids affect the lower urinary tract, they may become clinically useful.

CBD Dosage For Interstitial Cystitis

To know how much CBD to take for Interstitial Cystitis, there have been studies where the subjects are given between 150mg CBD, 300mg CBD up to 600mg CBD. Results said that the 300mg dose of CBD reduces pelvic pain significantly.

Sexologist and author Dr. Sadie Allison, and CBD scientist John Renko, B.S.E. created GoLove’s CBD lubricant specifically to enhance wellness and sexual health. As a result, it can help relax pelvic floor muscles and reduce any discomfort and inflammation that Interstitial Cystitis may cause. In case you want to learn more about this, you can read our article about the best lube for Interstitial Cystitis .

GoLove CBD Lubricant comes in several sizes, 40ml with 200mg of CBD and 5ml with 25mg of CBD, and these concentrations are high enough to be effective and safe. Besides, anyone can use it as GoLove is water-based, hypoallergenic, latex-safe, and pH-balanced.

Medical Cannabis for Gynecologic Pain Conditions: A Systematic Review

Objective: The endocannabinoid system is involved in pain perception and inflammation. Cannabis contains delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD), which are cannabinoids that bind to endocannabinoid system receptors. A fatty acid amide called palmitoylethanolamide (PEA) enhances endogenous cannabinoids. Given that use of medical cannabis is increasing, we sought to characterize patterns of cannabis use for gynecologic pain and its effectiveness as an analgesic.

Data sources: We searched PubMed, EMBASE, Scopus, Cochrane, and ClinicalTrials.gov using terms for “woman,” “cannabis,” and “pain” or “pelvic pain” or “endometriosis” or “bladder pain” or “cancer.” The search was restricted to English-language articles published between January 1990 and April 2021 and excluded animal studies.

Methods of study selection: The initial search yielded 5,189 articles with 3,822 unique citations. Studies were included if they evaluated nonpregnant adult women who used cannabinoids for gynecologic pain conditions (eg, chronic pelvic pain, vulvodynia, endometriosis, interstitial cystitis, malignancy). Study types included were randomized controlled trials (RCTs), cohort studies, and cross-sectional studies. Covidence systematic review software was used.

Tabulation, integration, and results: Fifty-nine studies were considered for full review, and 16 met inclusion criteria. Prevalence of cannabis use ranged from 13% to 27%. Most women ingested or inhaled cannabis and used cannabis multiple times per week, with dosages of THC and CBD up to 70 mg and 2,000 mg, respectively. Sixty-one to 95.5% reported pain relief. All six prospective cohort studies and one RCT of PEA-combination medications reported significant pain relief, and the average decrease in pain after 3 months of treatment was 3.35±1.39 on the 10-point visual analog scale. However, one fatty acid amide enzyme inhibitor RCT did not show pain reduction.

Conclusion: Survey data showed that most women reported that cannabis improved pain from numerous gynecologic conditions. Cohort studies and an RCT using PEA-combination medications reported pain reduction. However, interpretation of the studies is limited due to varying cannabis formulations, delivery methods, and dosages that preclude a definitive statement about cannabis for gynecologic pain relief.

Systematic review registration: PROSPERO, CRD42021248057.

Copyright © 2022 by the American College of Obstetricians and Gynecologists. Published by Wolters Kluwer Health, Inc. All rights reserved.

Conflict of interest statement

Financial Disclosure Jenell S. Coleman holds investments in a cannabis exchange-traded fund. The other authors did not report any potential conflicts of interest.

Similar articles

Mücke M, Phillips T, Radbruch L, Petzke F, Häuser W. Mücke M, et al. Cochrane Database Syst Rev. 2018 Mar 7;3(3):CD012182. doi: 10.1002/14651858.CD012182.pub2. Cochrane Database Syst Rev. 2018. PMID: 29513392 Free PMC article. Review.

McLoughlin BC, Pushpa-Rajah JA, Gillies D, Rathbone J, Variend H, Kalakouti E, Kyprianou K. McLoughlin BC, et al. Cochrane Database Syst Rev. 2014 Oct 14;(10):CD004837. doi: 10.1002/14651858.CD004837.pub3. Cochrane Database Syst Rev. 2014. PMID: 25314586 Review.

Maurer GE, Mathews NM, Schleich KT, Slayman TG, Marcussen BL. Maurer GE, et al. Sports Health. 2020 Nov/Dec;12(6):540-546. doi: 10.1177/1941738120956604. Epub 2020 Sep 16. Sports Health. 2020. PMID: 32936058 Free PMC article. Review.

Rabgay K, Waranuch N, Chaiyakunapruk N, Sawangjit R, Ingkaninan K, Dilokthornsakul P. Rabgay K, et al. J Am Pharm Assoc (2003). 2020 Jan-Feb;60(1):225-234.e6. doi: 10.1016/j.japh.2019.07.015. Epub 2019 Sep 5. J Am Pharm Assoc (2003). 2020. PMID: 31495691

Aviram J, Samuelly-Leichtag G. Aviram J, et al. Pain Physician. 2017 Sep;20(6):E755-E796. Pain Physician. 2017. PMID: 28934780 Review.